Researchers at Novoheart have created functional mini heart organoids, which are the first of their kind to contain chambers, like those found in fully grown human hearts. This advancement in stem cell engineering will expedite drug trials, which could bring potential cures to those who need them much sooner. Typically, new drugs take many years and require exorbitant resources to bring them to market, but Novoheart’s mini heart organoids look to disrupt the status quo and speed up the development of treatment options. Since these hearts have tissues differentiated from adult stem cells, the organoids behave and react to treatments like real hearts would, which allows researchers to detect and eliminate detrimental side effects long before reaching clinical trials. Additionally, the heart organoids can be used to understand cardiovascular diseases, which affect millions of people around the world.
Novoheart’s revolutionary differentiation protocol directs the stem cells to develop into fully functioning 3D chambered hearts on a micro scale whereas current organoids are created on a 2D platform. In addition to the heart organoids, researchers are applying the differentiation protocol to other organs and tissue with the aim of growing virtually any [micro] organoid that can then be utilized to expedite treatment development for a broad range of disease, trauma and injury. This technology also underscores the wisdom of banking stem cells, given that when a patient’s own stem cells are used, doctors and researchers could potentially analyze the personalized effect a particular treatment could have on the patient, without undergoing the risk of side effects.
To learn more about stem cells, and how families can bank their own valuable stem cells by recovering the very powerful dental pulp stem cells during routine dental procedures; such as wisdom teeth extractions or the during the loss of baby teeth, visit StemSave or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.